News | January 31, 2026
Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
Subscribe To Our Newsletter & Stay Updated
